[
  {
    "question": "75 years old patient with progressive cognitive decline chorea & Ataxia, (I think mention orolingual dystonia) has no children, his father died at age of 65 years, what is the most likely diagnosis:",
    "option_a": "Huntington.",
    "option_b": "Neuroacanthocytosis.",
    "option_c": "DRBLA?",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive Supranuclear Palsy (PSP) is a neurodegenerative tauopathy characterized by parkinsonism with a predominance of axial rigidity, postural instability with frequent falls, and a very distinctive supranuclear vertical gaze palsy. This vertical gaze abnormality\u2014especially affecting upward gaze\u2014is a key clinical clue that helps distinguish PSP from other parkinsonian syndromes. PSP is associated with abnormal accumulation of tau protein (4-repeat tau isoforms) leading to neurofibrillary tangles. This pathology is most prominent in the brainstem, basal ganglia, and frontal cortex. The degeneration of neurons in regions such as the rostral midbrain underlies the impairment of vertical gaze as well as axial rigidity and postural instability. Clinically, patients present with early postural instability, falls, axial rigidity, and difficulty with vertical eye movements. The presence of a supranuclear gaze palsy\u2014typically starting with impaired voluntary vertical eye movement\u2014is a hallmark and distinguishes PSP from idiopathic Parkinson\u2019s disease, where eye movement abnormalities (if they occur) are usually late in the disease. The differential diagnoses include Parkinson\u2019s disease (asymmetric onset, resting tremor, typically preserved early vertical gaze), Multiple System Atrophy (prominent autonomic dysfunction and cerebellar signs), Corticobasal Degeneration (asymmetric rigidity, apraxia, alien limb phenomenon), and Dementia with Lewy Bodies. Brain imaging often reveals midbrain atrophy (\u2018hummingbird sign\u2019) which supports the diagnosis of PSP. There is no disease\u2010modifying therapy for PSP; management is symptomatic. Levodopa trials may be attempted although benefit is often minimal. Supportive care, including physical, occupational, and speech therapy, is crucial along with fall prevention strategies. Given that PSP predominantly affects older adults, pregnancy and lactation issues are generally not applicable; however, for younger patients with parkinsonian syndromes, medication safety profiles must be considered. In typical parkinsonian syndromes: Parkinson\u2019s Disease usually shows asymmetric onset with resting tremor and only later develops eye movement abnormalities; Multiple System Atrophy involves significant autonomic failure; Corticobasal Degeneration is often asymmetric with cortical sensory disturbances and alien limb; Dementia with Lewy Bodies is marked by early cognitive decline and visual hallucinations. Only PSP presents with the classic triad of axial rigidity, parkinsonism, and vertical supranuclear gaze palsy, making it the correct choice. \u2022 Vertical supranuclear gaze palsy is a pathognomonic sign of PSP.  \u2022 The \u2018hummingbird sign\u2019 on midbrain imaging is a supportive diagnostic feature.  \u2022 Poor or minimal response to levodopa is common in PSP. Recent research continues to investigate tau-targeted therapies for PSP, though current management remains symptomatic. International consensus guidelines emphasize early recognition of the gaze palsy and appropriate supportive measures to improve quality of life.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Deep brain stimulation (DBS) of the globus pallidus interna (GPi) may be more effective than DBS of the subthalamic nucleus (STN) in treating which of the following features of Parkinson\u2019s disease?",
    "option_a": "Bradykinesia",
    "option_b": "Dementia",
    "option_c": "Dyskinesias",
    "option_d": "On-off fluctuations",
    "option_e": "Tremor",
    "correct_answer": "C",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive Supranuclear Palsy (PSP) is a neurodegenerative tauopathy characterized by parkinsonism with a predominance of axial rigidity, postural instability with frequent falls, and a very distinctive supranuclear vertical gaze palsy. This vertical gaze abnormality\u2014especially affecting upward gaze\u2014is a key clinical clue that helps distinguish PSP from other parkinsonian syndromes. PSP is associated with abnormal accumulation of tau protein (4-repeat tau isoforms) leading to neurofibrillary tangles. This pathology is most prominent in the brainstem, basal ganglia, and frontal cortex. The degeneration of neurons in regions such as the rostral midbrain underlies the impairment of vertical gaze as well as axial rigidity and postural instability. Clinically, patients present with early postural instability, falls, axial rigidity, and difficulty with vertical eye movements. The presence of a supranuclear gaze palsy\u2014typically starting with impaired voluntary vertical eye movement\u2014is a hallmark and distinguishes PSP from idiopathic Parkinson\u2019s disease, where eye movement abnormalities (if they occur) are usually late in the disease. The differential diagnoses include Parkinson\u2019s disease (asymmetric onset, resting tremor, typically preserved early vertical gaze), Multiple System Atrophy (prominent autonomic dysfunction and cerebellar signs), Corticobasal Degeneration (asymmetric rigidity, apraxia, alien limb phenomenon), and Dementia with Lewy Bodies. Brain imaging often reveals midbrain atrophy (\u2018hummingbird sign\u2019) which supports the diagnosis of PSP. There is no disease\u2010modifying therapy for PSP; management is symptomatic. Levodopa trials may be attempted although benefit is often minimal. Supportive care, including physical, occupational, and speech therapy, is crucial along with fall prevention strategies. Given that PSP predominantly affects older adults, pregnancy and lactation issues are generally not applicable; however, for younger patients with parkinsonian syndromes, medication safety profiles must be considered. In typical parkinsonian syndromes: Parkinson\u2019s Disease usually shows asymmetric onset with resting tremor and only later develops eye movement abnormalities; Multiple System Atrophy involves significant autonomic failure; Corticobasal Degeneration is often asymmetric with cortical sensory disturbances and alien limb; Dementia with Lewy Bodies is marked by early cognitive decline and visual hallucinations. Only PSP presents with the classic triad of axial rigidity, parkinsonism, and vertical supranuclear gaze palsy, making it the correct choice. \u2022 Vertical supranuclear gaze palsy is a pathognomonic sign of PSP.  \u2022 The \u2018hummingbird sign\u2019 on midbrain imaging is a supportive diagnostic feature.  \u2022 Poor or minimal response to levodopa is common in PSP. Recent research continues to investigate tau-targeted therapies for PSP, though current management remains symptomatic. International consensus guidelines emphasize early recognition of the gaze palsy and appropriate supportive measures to improve quality of life.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Site of Deep brain stimulation for the tremor:",
    "option_a": "Thalamus",
    "option_b": "GPi.",
    "option_c": "STN.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive Supranuclear Palsy (PSP) is a neurodegenerative tauopathy characterized by parkinsonism with a predominance of axial rigidity, postural instability with frequent falls, and a very distinctive supranuclear vertical gaze palsy. This vertical gaze abnormality\u2014especially affecting upward gaze\u2014is a key clinical clue that helps distinguish PSP from other parkinsonian syndromes. PSP is associated with abnormal accumulation of tau protein (4-repeat tau isoforms) leading to neurofibrillary tangles. This pathology is most prominent in the brainstem, basal ganglia, and frontal cortex. The degeneration of neurons in regions such as the rostral midbrain underlies the impairment of vertical gaze as well as axial rigidity and postural instability. Clinically, patients present with early postural instability, falls, axial rigidity, and difficulty with vertical eye movements. The presence of a supranuclear gaze palsy\u2014typically starting with impaired voluntary vertical eye movement\u2014is a hallmark and distinguishes PSP from idiopathic Parkinson\u2019s disease, where eye movement abnormalities (if they occur) are usually late in the disease. The differential diagnoses include Parkinson\u2019s disease (asymmetric onset, resting tremor, typically preserved early vertical gaze), Multiple System Atrophy (prominent autonomic dysfunction and cerebellar signs), Corticobasal Degeneration (asymmetric rigidity, apraxia, alien limb phenomenon), and Dementia with Lewy Bodies. Brain imaging often reveals midbrain atrophy (\u2018hummingbird sign\u2019) which supports the diagnosis of PSP. There is no disease\u2010modifying therapy for PSP; management is symptomatic. Levodopa trials may be attempted although benefit is often minimal. Supportive care, including physical, occupational, and speech therapy, is crucial along with fall prevention strategies. Given that PSP predominantly affects older adults, pregnancy and lactation issues are generally not applicable; however, for younger patients with parkinsonian syndromes, medication safety profiles must be considered. In typical parkinsonian syndromes: Parkinson\u2019s Disease usually shows asymmetric onset with resting tremor and only later develops eye movement abnormalities; Multiple System Atrophy involves significant autonomic failure; Corticobasal Degeneration is often asymmetric with cortical sensory disturbances and alien limb; Dementia with Lewy Bodies is marked by early cognitive decline and visual hallucinations. Only PSP presents with the classic triad of axial rigidity, parkinsonism, and vertical supranuclear gaze palsy, making it the correct choice. \u2022 Vertical supranuclear gaze palsy is a pathognomonic sign of PSP.  \u2022 The \u2018hummingbird sign\u2019 on midbrain imaging is a supportive diagnostic feature.  \u2022 Poor or minimal response to levodopa is common in PSP. Recent research continues to investigate tau-targeted therapies for PSP, though current management remains symptomatic. International consensus guidelines emphasize early recognition of the gaze palsy and appropriate supportive measures to improve quality of life.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient on metoclopramide, developed dystonia, what is the treatment.",
    "option_a": "trihexamethazin (trihexphenidyl?)",
    "option_b": "Levodopa",
    "option_c": "Dihydrotetrabenazine",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Drug\u2010induced acute dystonic reactions are a well\u2010recognized side effect of dopamine receptor antagonists such as metoclopramide. They occur due to an imbalance between dopaminergic and cholinergic activity within the basal ganglia. Metoclopramide blocks dopamine D2 receptors, leading to an excess of cholinergic activity. This imbalance is responsible for the acute muscle contractions and abnormal posturing characteristic of dystonia. The rapid onset after administration supports a drug-induced mechanism. Patients present with sudden, involuntary muscle spasms or abnormal postures (e.g., twisting of the neck or face) shortly after taking metoclopramide. Recognizing the temporal relationship between drug exposure and symptom onset is critical in making the diagnosis. The diagnosis is primarily clinical, based on history and physical examination. Differential diagnoses include tardive dyskinesia (which develops with longer-term use), acute akathisia, and other movement disorders. A clear drug history confirms the association. First-line treatment is prompt administration of anticholinergic medications. Agents such as benztropine, diphenhydramine, or trihexyphenidyl (as used in this case) are effective in restoring the neurotransmitter balance. In pregnant or lactating patients, the risks and benefits of anticholinergics need to be evaluated; however, if symptoms are severe, these agents may be used under close supervision. Option A (trihexyphenidyl) is correct because it is an anticholinergic agent that counteracts the dopaminergic-cholinergic imbalance. Option B (Levodopa) is used for the treatment of Parkinson\u2019s disease and does not address the acute dystonic state. Option C (Dihydrotetrabenazine) is more appropriate for treating hyperkinetic movement disorders such as tardive dyskinesia, not acute dystonia. Option D is not provided. 1. Acute dystonia from drugs like metoclopramide often occurs in younger patients. 2. An anticholinergic medication is the therapy of choice. 3. Recognize the temporal relationship between drug administration and symptom onset. Recent clinical guidelines and research reaffirm the use of anticholinergics for managing acute dystonic reactions. Rapid recognition and treatment are emphasized to prevent prolonged patient distress and potential complications.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Benefit of Deep brain stimulation of the subthalamic nucleus:",
    "option_a": "Dyskinesia.",
    "option_b": "Tremor.",
    "option_c": "Dystonia.",
    "option_d": "Reduction of the dopaminergic medication.",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Movement Disorders",
    "explanation": "Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) is an advanced surgical treatment for Parkinson\u2019s disease. It aims to modulate abnormal neural activity in the basal ganglia circuitry. By delivering high-frequency electrical impulses to the STN, DBS disrupts the pathologic neuronal firing patterns inherent in Parkinson\u2019s disease. This modulation helps improve motor symptoms and reduces complications associated with long-term dopaminergic therapy. Patients with advanced Parkinson\u2019s disease typically experience motor fluctuations and dyskinesia from prolonged levodopa usage. STN-DBS can improve overall motor function while significantly reducing the required dopaminergic medication dosage, with subsequent improvement in dyskinesias. Candidate selection for DBS involves a comprehensive evaluation including a levodopa challenge test, neuroimaging, and neuropsychological analysis. Differentiating Parkinson\u2019s disease from atypical parkinsonism is important, as the latter may not respond as robustly to DBS. While initial management of Parkinson\u2019s disease is pharmacologic (using levodopa and dopamine agonists), DBS is considered in advanced cases with motor fluctuations. Postoperative management includes careful titration of medications to optimize outcomes. In cases involving pregnancy or lactation, DBS is rarely performed due to surgical risks; medical management remains the cornerstone with careful planning. Option D (Reduction of the dopaminergic medication) is correct since one of the most significant benefits of STN-DBS is the ability to lower the dose of dopaminergic medication, thus reducing related side effects such as dyskinesia. Options A (Dyskinesia), B (Tremor), and C (Dystonia) may improve as a consequence of reduced medication doses, but the principal benefit and one that is heavily considered during patient selection is the medication reduction aspect. 1. STN-DBS is particularly effective in reducing levodopa-induced motor complications. 2. A substantial reduction in medication can decrease dyskinesia. 3. Proper candidate selection is critical for optimal outcomes. Recent studies and guidelines support STN-DBS as an effective intervention for advanced Parkinson\u2019s disease. Long-term follow-up data indicate sustained improvement in motor function and significant reduction in dopaminergic medication requirements.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with visual hallucination & fluctuating LOC, symptoms suggesting parkinsonism:",
    "option_a": "Lewi Body disease.",
    "option_b": "Idiopathic Parkinson",
    "option_c": "ALS",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Dementia with Lewy bodies (DLB), also referred to as Lewy Body disease, is a neurodegenerative disorder that manifests with a combination of parkinsonism, cognitive fluctuations, and visual hallucinations. DLB is characterized by the abnormal accumulation of alpha-synuclein proteins forming Lewy bodies in cortical and subcortical regions. This protein deposition disrupts neurotransmission, accounting for the hallmark symptoms such as fluctuating cognition, visual hallucinations, and motor features. Patients with DLB typically present with early and prominent visual hallucinations along with fluctuating levels of consciousness and parkinsonian motor symptoms (rigidity, bradykinesia). This triad differentiates DLB from other neurodegenerative conditions like Alzheimer\u2019s or idiopathic Parkinson\u2019s disease. Diagnosis is largely clinical, supported by imaging (e.g., dopamine transporter scans) and neuropsychological testing. Differential diagnoses include idiopathic Parkinson\u2019s disease (where cognitive decline occurs later) and Alzheimer\u2019s disease. The early presence of visual hallucinations and fluctuating alertness strongly suggests DLB. Management of DLB focuses on symptomatic treatment. Cholinesterase inhibitors (e.g., rivastigmine) are considered first-line for cognitive and behavioral symptoms, while antipsychotics are used very cautiously due to severe sensitivity reactions. Given that DLB predominantly affects older adults, pregnancy and lactation are rarely concerns; however, in younger patients where these issues arise, a thorough risk-benefit analysis is essential. Option A (Lewy Body disease) is correct because the combination of visual hallucinations, fluctuating level of consciousness, and parkinsonism is most characteristic of DLB. Option B (Idiopathic Parkinson\u2019s disease) typically presents primarily with motor symptoms and later cognitive decline. Option C (ALS) involves motor neuron degeneration and does not present with the described cognitive and visual hallucination features. 1. Early visual hallucinations in the context of parkinsonian features point toward DLB. 2. Neuroleptic sensitivity is a major consideration in treating patients with DLB. 3. Fluctuating cognition is a key diagnostic clue. Current research and guidelines emphasize early recognition of DLB given its distinct therapeutic challenges. Recent studies also continue to evaluate the role of cholinesterase inhibitors and other symptomatic treatments in improving patient outcomes.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "young patient complaining of hearing impairment, she has ataxia, dizziness & nystagmus, working in industry her sister has dizziness & depression, the head impulse is normal, what is the most likely diagnosis.",
    "option_a": "Meniere disease.",
    "option_b": "Episodic ataxia type 2",
    "option_c": "Perilymph fistula",
    "option_d": "BPPV.",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Episodic Ataxia Type 2 (EA2) is an autosomal dominant disorder characterized by recurrent episodes of ataxia, vertigo, and nystagmus. It represents a central, rather than a peripheral, vestibular pathology. EA2 is most commonly caused by mutations in the CACNA1A gene, which encodes a P/Q-type voltage-gated calcium channel. Dysfunction in these channels leads to impaired cerebellar signaling and episodic incoordination. Although hearing impairment is not as prominent as the ataxia and vertigo, variable expressivity can sometimes include mild auditory symptoms. Patients typically experience episodic bouts of ataxia, dizziness, and nystagmus. A normal head impulse test is indicative of a central cause rather than a peripheral vestibular disorder. The familial pattern, as suggested by the affected sister, strengthens the diagnosis of a genetic condition like EA2. Diagnosis is based on clinical history, family history (given its autosomal dominant inheritance), and a normal head impulse test which suggests central vertigo. Differential diagnoses include Meniere\u2019s disease (typically peripheral with an abnormal head impulse test and more pronounced unilateral hearing loss), perilymph fistula (usually following trauma with peripheral findings), and BPPV (which does not cause hearing impairment and is diagnosed via positional maneuvers). First-line treatment for EA2 is acetazolamide, which has been shown to reduce the frequency and severity of ataxic episodes. In some cases, 5-aminopyridine may be considered. In pregnant or lactating patients, the use of acetazolamide requires careful risk-benefit assessment due to potential teratogenicity and effects on lactation; such decisions should be made in consultation with neurology and obstetrics specialists. Option B (Episodic ataxia type 2) is correct. Option A (Meniere disease) typically presents as a peripheral vestibular disorder with abnormal head impulse testing and is not usually familial. Option C (Perilymph fistula) is associated with trauma or barometric changes and also demonstrates peripheral deficits. Option D (BPPV) is characterized by brief episodes of vertigo related to positional changes and does not include hearing impairment. 1. A normal head impulse test in a vertiginous patient suggests a central origin of symptoms. 2. EA2 is an autosomal dominant disorder; family history is a key diagnostic clue. 3. Acetazolamide is the treatment of choice for reducing episodic symptoms in EA2. Recent genetic and clinical studies continue to validate acetazolamide as the primary treatment for EA2. Advances in genetic testing have improved diagnostic accuracy, and ongoing research is exploring additional targeted therapies and more detailed genotype-phenotype correlations.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "9 years old boy with hx of 14 months vocal & motor tics & hx of OCD, what is the Dx:",
    "option_a": "Tourette syndrome.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Tourette syndrome is a neurodevelopmental disorder defined by the presence of both multiple motor tics and at least one vocal tic persisting for more than one year. It typically begins in childhood and is often associated with comorbid conditions such as obsessive-compulsive disorder (OCD) and attention deficit hyperactivity disorder (ADHD). The condition is thought to result from dysfunction within cortico-striato-thalamo-cortical circuits with dysregulation of dopaminergic neurotransmission. Neuroimaging studies have identified abnormalities in the basal ganglia (caudate nucleus and putamen). Genetic predisposition also plays a role, with several susceptibility loci identified in recent research. In the clinical scenario\u2014a 9-year-old boy with a 14-month history of both vocal and motor tics plus a history of OCD\u2014the diagnostic criteria for Tourette syndrome are clearly met. Symptoms tend to wax and wane in severity and may be exacerbated by stress, while comorbid OCD is a common finding that impacts the quality of life. Diagnosis is primarily clinical and based on DSM-5 criteria. Differential diagnoses include chronic tic disorder (if either vocal or motor tics are absent) and transient tic disorder (if duration is less than one year). A careful neuropsychiatric evaluation is important to document comorbidities like OCD and ADHD. Initial management involves behavioral interventions such as habit reversal training and psychoeducation. First\u2010line pharmacotherapy includes alpha-2 agonists (e.g., clonidine or guanfacine), particularly when tics are mild to moderate. In more severe cases, atypical antipsychotics (e.g., risperidone) may be considered. For patients who are pregnant or lactating, non-pharmacologic measures are preferred due to potential medication risks. Treatment of coexisting OCD is usually managed with selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy. Option A (Tourette syndrome) is correct because the patient presents with both motor and vocal tics for over a year with comorbid OCD. Other options, if provided, might refer to less specific tic disorders that do not meet all the diagnostic criteria. 1. Tourette syndrome requires both motor and vocal tics present over at least one year for diagnosis. 2. Comorbid OCD is common and may require separate management. 3. Behavioral therapies are the cornerstone of initial management. Recent guidelines emphasize a multimodal approach combining behavioral and pharmacologic strategies. Ongoing research is exploring the neural underpinnings of tic disorders, with emerging therapies like deep brain stimulation being evaluated for treatment-resistant cases.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "young man with orolingual dystonia, associated with cognitive deficit, there is no family hx:",
    "option_a": "peripheral blood film for acanthocyte.",
    "option_b": "Htt gene",
    "option_c": "Slit lamb examination",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "The presentation\u2014a young man with orolingual dystonia and cognitive deficits in the absence of a family history\u2014raises suspicion for a neuroacanthocytosis syndrome, a group of disorders that combine neurological manifestations with acanthocytosis (spiky red blood cells) seen on peripheral smear. Neuroacanthocytosis syndromes, such as chorea-acanthocytosis, involve neurodegeneration in the basal ganglia along with abnormalities in red blood cell membrane proteins, leading to the characteristic acanthocytes. The exact mechanisms vary by subtype, with some forms inherited in an autosomal recessive manner, contributing to the absence of a family history in some cases. Orolingual dystonia is a hallmark of these conditions and may present with involuntary, repetitive movements affecting the mouth and face. Cognitive impairment further supports a neurodegenerative process, and the absence of a clear family history may be seen in recessive disorders or sporadic cases. The simplest and most informative initial test is a peripheral blood smear to evaluate for acanthocytes. Differential diagnoses include Huntington\u2019s disease (typically with a positive family history and confirmed by Htt gene mutation testing) and Wilson\u2019s disease (which would be evaluated using a slit lamp exam for Kayser-Fleischer rings and copper studies). Management is largely symptomatic and supportive. Treatment for dystonia may involve medications such as dopamine depleting agents or botulinum toxin injections, while cognitive deficits are managed with neuropsychiatric support and rehabilitation. In pregnant or lactating women, any pharmacologic therapy must be chosen with careful consideration of fetal and neonatal safety, balancing symptom control with potential risks. Option A (peripheral blood film for acanthocyte) is the appropriate initial test given the clinical context. Option B (Htt gene) would be directed toward a diagnosis of Huntington\u2019s disease, which is less likely here due to the absence of a familial pattern. Option C (slit lamp examination) is primarily used to evaluate for Wilson\u2019s disease and does not fit the orolingual dystonia profile associated with neuroacanthocytosis. 1. Acanthocytes on a peripheral blood smear can be a key diagnostic clue in neuroacanthocytosis syndromes. 2. Orolingual dystonia paired with cognitive decline should prompt evaluation for neurodegenerative disorders. 3. Always consider the pattern of inheritance when family history is absent. Current research is focused on improving diagnostic criteria through genetic and biomarker studies. While no curative treatment exists, multidisciplinary management strategies are recommended, and studies continue to evaluate potential disease-modifying therapies.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Pt w bilateral tremors her father have the same tremor Rx??",
    "option_a": "Propranolol",
    "option_b": "levodopa",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Essential tremor is a common movement disorder that typically presents as a bilateral, action or postural tremor. It often runs in families, underscoring a genetic component. The pathogenesis of essential tremor is not fully understood but is believed to involve abnormal oscillatory activity in the cerebello-thalamo-cortical circuit. There is evidence of genetic predisposition, and autosomal dominant inheritance is frequently observed in familial cases. In this scenario, the patient\u2019s bilateral tremors with a positive family history strongly suggest essential tremor. The tremor is most noticeable when the affected limbs are in use (action tremor) rather than at rest, differentiating it from Parkinson\u2019s disease. Diagnosis is clinical, based on history and examination. Differential diagnoses include Parkinson\u2019s disease (which features a resting tremor with additional parkinsonian features like rigidity and bradykinesia) and cerebellar tremor (characterized by intention tremor and ataxia). Electrophysiological studies or imaging are rarely needed unless atypical features are present. First-line treatment includes nonselective beta-blockers (e.g., propranolol) or primidone. Propranolol is particularly effective in reducing tremor amplitude. In patients who are pregnant or lactating, caution is advised with beta-blockers because of potential fetal growth restriction and neonatal effects; dosage adjustments and close monitoring are required. Primidone is generally avoided during pregnancy due to concerns about teratogenicity. Option A (Propranolol) is correct as it is the first-line treatment for essential tremor. Option B (Levodopa) is typically used for Parkinson\u2019s disease, which is characterized by a resting tremor and other motor symptoms not seen in familial essential tremor. 1. Essential tremor is often familial and presents as an action tremor. 2. Propranolol and primidone are first-line treatments. 3. Differentiating essential tremor from Parkinson\u2019s disease is key, particularly noting the tremor type (action vs. resting). Recent advancements in our understanding of the cerebellar involvement in essential tremor have spurred interest in neuromodulatory treatments like focused ultrasound thalamotomy for refractory cases. Updated clinical guidelines continue to endorse beta-blockers and primidone as first-line therapies.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Male patient presenting with parkinsonism and swallowing difficulty, midbrain is atrophied?",
    "option_a": "PSP",
    "option_b": "MSA",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive Supranuclear Palsy (PSP) is an atypical parkinsonian syndrome characterized by early gait instability, postural instability, dysphagia, and vertical gaze palsy. Midbrain atrophy is a key neuroimaging finding that helps distinguish it from other parkinsonian disorders. PSP is a tauopathy marked by abnormal accumulation of tau protein in the brain, particularly within the brainstem, basal ganglia, and frontal lobes. This pathological process leads to neurodegeneration, with the midbrain commonly affected, producing the \u2018hummingbird sign\u2019 on MRI. The patient's presentation of parkinsonism combined with swallowing difficulties (dysphagia) is reflective of PSP. The imaging finding of midbrain atrophy is classic for this condition. PSP patients often experience early falls and limitations in vertical gaze, which further support the diagnosis. Diagnosis of PSP is clinical, supported by neuroimaging. Differential diagnoses include Multiple System Atrophy (MSA), which typically has significant autonomic dysfunction and cerebellar findings, and idiopathic Parkinson\u2019s disease, which generally shows a good response to levodopa and has resting tremor as a hallmark. Management of PSP is largely supportive. First-line interventions include physiotherapy and speech/swallowing therapy to help manage dysphagia and maintain mobility. A trial of levodopa is often attempted but typically shows minimal benefit. In pregnant patients, pharmacologic interventions are cautiously used; supportive and rehabilitative therapies are prioritized, as there is no proven disease-modifying treatment for PSP. Research into tau-directed therapies is ongoing. Option A (PSP) is correct given the combination of parkinsonism, dysphagia, and midbrain atrophy. Option B (MSA) is less likely because MSA usually features autonomic dysfunction and cerebellar or pontine changes rather than isolated midbrain atrophy. 1. PSP should be considered in patients with early falls, dysphagia, and vertical gaze palsy. 2. The \u2018hummingbird sign\u2019 on MRI is highly suggestive of PSP. 3. Levodopa response is minimal in PSP compared to Parkinson\u2019s disease. Recent studies are increasingly focusing on tauopathies, with clinical trials investigating tau-targeting and neuroprotective agents in PSP. Current clinical guidelines emphasize a multidisciplinary and supportive approach due to the lack of an effective disease-modifying therapy.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Pt w parkinsonism and ataxia & falls and orthostatic attached MRI w hot cross bun sign dx?",
    "option_a": "MSA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Multiple System Atrophy (MSA) is a sporadic, progressive neurodegenerative disorder that presents with a combination of parkinsonism, cerebellar ataxia, and autonomic dysfunction. In this patient, the concurrent presence of parkinsonism, ataxia, frequent falls, and orthostatic hypotension, along with the characteristic MRI 'hot cross bun' sign, points toward MSA, particularly the cerebellar variant (MSA-C). MSA is characterized by the accumulation of alpha-synuclein within oligodendrocytes, leading to widespread neuronal degeneration in multiple neural systems including the striatonigral (leading to parkinsonian features) and olivopontocerebellar systems (causing ataxia). The 'hot cross bun' sign on MRI represents the degeneration of the pontocerebellar fibers in the pons and is a radiological hallmark, particularly associated with MSA-C. Patients with MSA often exhibit motor symptoms similar to Parkinson\u2019s disease, but the additional presence of cerebellar signs (ataxia) and profound autonomic dysfunction (e.g., orthostatic hypotension, urinary incontinence, and erectile dysfunction) help differentiate it from idiopathic Parkinson\u2019s disease. The MRI findings further support the diagnosis. Diagnosis is made clinically by the combination of motor, cerebellar, and autonomic symptoms, supported by MRI findings like the 'hot cross bun' sign. Differential diagnoses include idiopathic Parkinson\u2019s disease (typically with a more robust and sustained levodopa response), other atypical parkinsonian syndromes, and spinocerebellar ataxias. Detailed autonomic testing and careful review of imaging can aid in differentiation. There is currently no disease-modifying treatment for MSA; management is primarily symptomatic. First-line management includes careful use of levodopa for parkinsonian features (although response may be limited) and medications such as midodrine or droxidopa for autonomic dysfunction. Non-pharmacologic measures like increased fluid and salt intake, compression stockings, and physical therapy are recommended. In pregnancy and lactation\u2014which are rarely concerns in the typical MSA patient\u2014any therapeutic agents require a careful risk-benefit analysis, with consultation of updated obstetric guidelines for vasoactive drugs. Option A (MSA) is correct because the clinical presentation combined with the MRI 'hot cross bun' sign is virtually pathognomonic for MSA. The absence of any alternative options further reinforces that MSA is the intended and correct diagnosis. 1) The 'hot cross bun' sign is a key radiological clue for MSA-C. 2) Autonomic dysfunction, particularly orthostatic hypotension, is a central feature in MSA. 3) MSA typically shows a poor and transient response to levodopa therapy compared to idiopathic Parkinson\u2019s disease. Recent research and updated diagnostic criteria emphasize the importance of MRI findings in distinguishing MSA from other parkinsonian disorders. Ongoing studies aim to identify biomarkers and potential disease-modifying therapies, although current management remains symptomatic.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "9 years old girl pt known case of developmental delay and has history of 10 month of abnormal postures and twitching of limbs with diurnal event. Genetic testing done and showed (gch1) What is the proper treatment? GCH1 gene.: (segawa syndrome) dopa-responsive dystonia DYT5, Autosomal dominant",
    "option_a": "Levodopa",
    "option_b": "carbamazepine",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Dopa-responsive dystonia (DRD), also known as Segawa syndrome or DYT5, is a rare movement disorder that typically presents in childhood with dystonia, abnormal posturing, and diurnal fluctuation (worsening in the evening). It is most often associated with a mutation in the GCH1 gene and follows an autosomal dominant inheritance pattern. DRD is caused by a mutation in the GCH1 gene, which encodes the enzyme GTP cyclohydrolase I \u2013 a critical enzyme in the synthesis of tetrahydrobiopterin (BH4), a cofactor necessary for dopamine synthesis. The deficiency in dopamine production in the basal ganglia leads to the dystonic symptoms seen in this syndrome. The diurnal variability is thought to be due to fluctuations in dopamine synthesis and its utilization throughout the day. Patients often present with lower limb dystonia, gait disturbances, and postural instability. The hallmark feature is the dramatic and sustained response to low-dose levodopa, which distinguishes it from other forms of dystonia. The presence of developmental delay in this young patient further aids in distinguishing it from other movement disorders of childhood. The diagnosis is based on the clinical presentation (diurnal fluctuation of dystonic symptoms), a positive family history (given autosomal dominant inheritance), and confirmation through genetic testing for GCH1 mutations. Differential diagnoses include cerebral palsy, other genetic dystonias, and juvenile parkinsonism; however, the response to levodopa is uniquely characteristic of DRD. The first-line treatment is low-dose levodopa, which typically produces a dramatic and sustained improvement in symptoms. Second-line management is rarely necessary because of the effective response to levodopa. For pregnant or lactating patients with DRD, levodopa is generally considered safe under careful monitoring, but a detailed obstetric assessment and individualized risk-benefit analysis should be performed. Option A (Levodopa) is correct as it is the definitive treatment for DRD due to GCH1 mutations. Option B (Carbamazepine) is not indicated for this condition, as it is primarily used for seizure disorders and certain types of movement disorders (like paroxysmal kinesigenic dyskinesia) but not for DRD. 1) DRD shows a dramatic response to low-dose levodopa, which is a key diagnostic and therapeutic clue. 2) Diurnal fluctuation of symptoms, with worsening in the evening, is typical. 3) Genetic testing for GCH1 mutations can confirm the diagnosis. Recent clinical guidelines and studies continue to support low-dose levodopa as the gold-standard treatment for DRD. There is growing evidence on the safety and effectiveness of levodopa in pediatric populations, and ongoing research is refining the genetic understanding of the condition.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "70 years old male pt k/c of Parkinson\u2019s disease 10 years back with good benefits to levodopa. He came with a picture of orthostatic hypotension and frequent falls, What is the diagnosis?",
    "option_a": "idiopathic Parkinson disease",
    "option_b": "MSA",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Idiopathic Parkinson\u2019s disease (PD) is a common neurodegenerative disease characterized by the classic motor symptoms of tremor, rigidity, bradykinesia, and postural instability. A good and sustained response to levodopa is a hallmark of PD. In advanced stages, non-motor manifestations such as autonomic dysfunction, including orthostatic hypotension, and frequent falls may occur. PD is primarily due to the degeneration of dopaminergic neurons in the substantia nigra pars compacta, with the presence of Lewy bodies being a characteristic pathological finding. As the disease progresses, non-motor pathways, including those regulating autonomic functions, may also become affected, leading to features such as orthostatic hypotension and gait instability. This 70-year-old patient, with a 10-year history of PD and a well-documented robust response to levodopa, now presents with orthostatic hypotension and frequent falls. The later appearance of significant autonomic dysfunction is consistent with the progression of idiopathic PD rather than a switch to an atypical parkinsonian syndrome like MSA, which is typically characterized by a poor response to levodopa from the outset. Diagnosis relies on clinical history and examination. Differential diagnoses include multiple system atrophy (MSA), especially when autonomic dysfunction is prominent; however, the sustained good response to levodopa over a decade strongly favors idiopathic PD. Other differential considerations include pure autonomic failure and Lewy body dementia, but the clinical context here supports idiopathic PD. First-line management of idiopathic PD involves dopaminergic therapies (e.g., levodopa, dopamine agonists, MAO-B inhibitors) tailored to the patient\u2019s symptoms. As the disease advances, non-motor symptoms, including orthostatic hypotension, are managed with both non-pharmacologic strategies (hydration, compression garments) and pharmacologic therapies (midodrine, fludrocortisone). Although pregnancy and lactation considerations are not relevant in an elderly male patient, these agents in general require careful management and risk-benefit analysis in women of childbearing age. Option A (Idiopathic Parkinson Disease) is correct due to the long-standing diagnosis and excellent levodopa responsiveness. Option B (MSA) is less likely since MSA typically shows poor or transient levodopa response and presents with prominent autonomic dysfunction early on, rather than after a decade of treatment. 1) A sustained and robust response to levodopa over many years is a key indicator of idiopathic PD. 2) Autonomic symptoms such as orthostatic hypotension can develop later in the disease course. 3) Differentiating idiopathic PD from MSA is critical because treatment strategies and prognoses differ significantly. Recent updates in PD management emphasize a comprehensive approach that targets both motor and non-motor symptoms. Current studies are investigating improved strategies for managing autonomic dysfunction, and recent guidelines outline tailored therapies based on disease stage, with a growing emphasis on individualized treatment plans.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Around 12 years old male patient had a history of runny nose 2 weeks ago. There was no fever, sore throat, presented with abnormal movement, attached a video, what\u2019s the diagnosis? Same as this video (https://youtu.be/wTCnbga3sqg)",
    "option_a": "Sydenham chorea",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Sydenham chorea is a neurological manifestation of acute rheumatic fever, classically seen in children following a group A streptococcal infection. It is characterized by rapid, involuntary, and purposeless movements (chorea), often emerging several weeks after a mild or even subclinical infection. The pathogenesis of Sydenham chorea is believed to involve an autoimmune mechanism wherein antibodies produced in response to a group A streptococcal infection mistakenly target antigens in the basal ganglia due to molecular mimicry. This immune-mediated process leads to dysfunction of the motor circuits in the brain, resulting in the characteristic choreiform movements. Typically affecting children between the ages of 5 and 15, Sydenham chorea presents with sudden onset of rapid, uncoordinated movements, which may interfere with voluntary motor tasks and lead to clumsiness or difficulty with coordinated activities. The history of a recent upper respiratory infection\u2014even if minor, such as a runny nose\u2014can be an important clue in the absence of overt pharyngitis or fever. The diagnosis is primarily clinical, supported by a history of a recent streptococcal infection and the emergence of choreiform movements. Laboratory investigations may include elevated anti-streptolysin O (ASO) titers and other markers of recent streptococcal infection. Differential diagnoses include PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections), other causes of childhood chorea (such as Wilson's disease, though age and additional features help differentiate), and medication-induced chorea. Treatment of Sydenham chorea involves addressing the underlying streptococcal infection to prevent recurrence, typically with penicillin or other appropriate antibiotics. Symptomatic management of chorea can include the use of drugs such as valproic acid or atypical antipsychotics if the movements are severely disabling. In most children, the condition is self-limiting and resolves over weeks to months. Pregnancy and lactation considerations are not applicable in this pediatric population, but if treatment were needed in older patients, guidelines would emphasize careful medication selection and dosage adjustments. Option A (Sydenham chorea) is correct because the patient\u2019s age, recent upper respiratory tract infection, and subsequent development of choreiform movements strongly suggest a diagnosis of Sydenham chorea. The absence of fever or sore throat does not rule out a previous streptococcal infection, which is often subclinical or minimally symptomatic. 1) Sydenham chorea is a classic post-streptococcal autoimmune phenomenon typically seen in children. 2) The interval between the streptococcal infection and the onset of chorea can be several weeks. 3) Despite the dramatic presentation, Sydenham chorea is usually self-limited with supportive care and appropriate antibiotic prophylaxis. Current guidelines for the management of acute rheumatic fever continue to include Sydenham chorea as a major criterion. Recent studies have reinforced the role of immunological mechanisms in its pathogenesis and emphasize prompt antibiotic therapy to reduce the risk of recurrent group A streptococcal infections. Ongoing research is exploring additional immunomodulatory treatments for severe or prolonged cases.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Case scenario of a patient with hemineglect myoclonic jerk and abnormal movement of one limb dx? MRI showed parietal atrophy",
    "option_a": "CBD\u2026",
    "option_b": "MSA",
    "option_c": "DLB",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "The question describes a patient with signs of cortical dysfunction (hemineglect) combined with abnormal limb movements (which may represent an alien limb phenomenon or myoclonic jerks) and neuroimaging showing parietal atrophy. This constellation of findings is classically seen in Corticobasal Degeneration (CBD), an atypical parkinsonian syndrome. CBD is a tauopathy characterized by the deposition of abnormal tau protein in neurons and glia that leads to progressive, asymmetric neurodegeneration. The predominance of parietal lobe involvement explains the hemineglect and apraxia seen in these patients. The asymmetry and cortical involvement set it apart from more typical forms of Parkinson\u2019s disease. Clinically, patients with CBD often exhibit asymmetric motor symptoms, cortical sensory deficits (such as hemineglect), apraxia, and alien limb phenomena. The presence of myoclonic jerks or abnormal movements can be part of this complex picture. Parietal atrophy on MRI further supports the clinical suspicion of CBD. Diagnosis of CBD is primarily clinical, supported by neuroimaging findings. MRI often shows asymmetric cortical atrophy (especially parietal) and signal changes. Differential diagnoses include other atypical parkinsonian syndromes such as Progressive Supranuclear Palsy (PSP), Diffuse Lewy Body disease (DLB), and Multiple System Atrophy (MSA), which can be differentiated by their distinct clinical features and imaging patterns. There are no disease\u2010modifying treatments for CBD. Management is symptomatic and supportive, including use of medications like low-dose levodopa (often with a poor response), muscle relaxants, and multidisciplinary supportive therapies (physical, occupational, and speech therapy). In advanced cases, palliative care measures become important. Given that this condition predominantly affects older adults, pregnancy and lactation considerations are generally not applicable. Option A (CBD) is correct because the signs of hemineglect, abnormal unilateral movements, and parietal lobe atrophy on MRI are highly suggestive of CBD. Option B (MSA) typically presents with severe autonomic dysfunction and cerebellar signs, while Option C (DLB) is more associated with cognitive fluctuations and visual hallucinations. Option D is not provided. 1. Asymmetric parietal lobe atrophy on MRI is a key radiological finding in CBD. 2. Cortical sensory deficits like hemineglect and the alien limb phenomenon are hallmark clinical features. Recent research in CBD is focusing on tau protein aggregation inhibitors and novel biomarkers. However, current management still revolves around symptomatic treatment and multidisciplinary care, as no disease-modifying therapy has been approved.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "pt w hallucination, parkinsonism and urinary incontinence dx?",
    "option_a": "DLB",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Dementia with Lewy Bodies (DLB) is a neurodegenerative disorder that commonly presents with a combination of cognitive decline, visual hallucinations, parkinsonism, and occasionally features of autonomic dysfunction such as urinary incontinence. DLB is a synucleinopathy characterized by the widespread deposition of Lewy bodies (aggregates of alpha-synuclein) within cortical and subcortical regions. This disrupts normal neuronal function leading to the core clinical features. Although autonomic dysfunction is more prominent in disorders like MSA, patients with DLB can also exhibit urinary incontinence as part of their clinical syndrome. The presence of hallucinations (typically visual), parkinsonian motor symptoms, and urinary incontinence supports a diagnosis of DLB. While cognitive fluctuations and neuroleptic sensitivity are also important aspects of DLB, the triad provided aligns well with this diagnosis. Differential considerations might include Parkinson\u2019s disease dementia or normal pressure hydrocephalus, but the hallucinations tip the scale toward DLB. Diagnosis of DLB is primarily clinical, supported by criteria such as the McKeith criteria. Neuroimaging (e.g., dopamine transporter scans) and careful clinical history help differentiate it from Alzheimer\u2019s disease, Parkinson\u2019s disease dementia, and other causes of cognitive impairment. Management of DLB typically involves cholinesterase inhibitors (e.g., rivastigmine) to help with cognitive and neuropsychiatric symptoms, and cautious use of dopaminergic agents for parkinsonism. Antipsychotic medications must be used with extreme caution due to high sensitivity. Since DLB mostly affects the elderly, pregnancy and lactation issues are not a concern. Option A (DLB) is correct as the constellation of hallucinations, parkinsonism, and incontinence points toward DLB. Alternative options would have been less consistent with this presentation; for example, MSA presents with marked autonomic failure and minimal hallucinations, while PSP and CBD present with different motor and cognitive profiles. 1. Visual hallucinations in conjunction with parkinsonism are a hallmark of DLB. 2. Neuroleptic sensitivity is severe in DLB, so antipsychotics should be used very judiciously. Current research is exploring therapies to reduce alpha-synuclein aggregation and improve early diagnostic biomarkers. Cholinesterase inhibitors remain the cornerstone of symptomatic management according to the latest consensus guidelines.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Around 70 yo male patient with history of urinal retention, syncope, memory impairment, later he developed laryngeal stridor MRI showed\nWhat is the diagnosis:",
    "option_a": "PSP",
    "option_b": "MSA",
    "option_c": "LBD",
    "option_d": "CBD",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "The patient is an elderly male presenting with autonomic dysfunction (urinary retention, syncope), memory impairment, and the development of laryngeal stridor. This combination, particularly the stridor associated with autonomic instability, is classically seen in Multiple System Atrophy (MSA). MSA is a neurodegenerative disease categorized as a synucleinopathy. It is marked by glial cytoplasmic inclusions containing alpha-synuclein. The degeneration in regions that control autonomic function leads to urinary retention and orthostatic hypotension (resulting in syncope), while involvement of respiratory muscles may lead to laryngeal stridor. The key features\u2014autonomic failure (urinary retention, syncope), parkinsonian signs, and the development of laryngeal stridor\u2014strongly support MSA. While memory impairment is not the most prominent feature of MSA, some degree of cognitive involvement can occur. This clinical picture helps distinguish MSA from other atypical parkinsonian syndromes. MSA is diagnosed based on clinical criteria (the Second Consensus Statement on the Diagnosis of MSA) with supportive findings on neuroimaging (e.g., atrophy of the putamen, cerebellum, or brainstem, and the 'hot cross bun' sign in MSA-C). Differentials include Progressive Supranuclear Palsy (PSP), which typically shows vertical gaze abnormalities, Diffuse Lewy Body Disease (which has prominent hallucinations), and CBD (which typically presents with asymmetric motor dysfunction without marked autonomic failure). Management of MSA is symptomatic. First-line treatments focus on managing autonomic dysfunction (e.g., using fludrocortisone or midodrine for hypotension) and parkinsonian features (a trial of levodopa may be attempted, though response is often limited). Laryngeal stridor may require interventions such as CPAP, or in severe cases, tracheostomy. Multidisciplinary care including physical therapy and occupational therapy is essential. In a 70-year-old male, pregnancy and lactation issues are not applicable, but in general, for women of childbearing potential, medication safety profiles must be considered. Option B (MSA) is correct because the hallmark features of autonomic dysfunction (urinary retention, syncope) and laryngeal stridor are best explained by MSA. Option A (PSP) would more typically involve early falls and vertical gaze palsy, Option C (LBD) is characterized by visual hallucinations and cognitive fluctuations, and Option D (CBD) shows more asymmetric motor findings without prominent autonomic involvement. 1. Laryngeal stridor in the context of autonomic symptoms strongly suggests MSA. 2. The 'hot cross bun' sign on MRI, although more common in the cerebellar variant (MSA-C), is a supportive imaging feature. Current research in MSA focuses on earlier diagnosis using advanced imaging and biomarkers. Although there is no disease-modifying therapy, recent trials are targeting alpha-synuclein aggregation. Management continues to be supportive with a multidisciplinary approach tailored to symptomatic relief.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "What is treatment with patient with PD and has Features RLS ? Dopamine agonist",
    "option_a": "Dopamine agonist",
    "option_b": "Gabapentin",
    "option_c": "Alaa movement 55",
    "option_d": "First line treatment",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) is a neurodegenerative disorder characterized by dopaminergic neuronal loss, while Restless Legs Syndrome (RLS) is a sleep\u2010related movement disorder thought to be associated with dopaminergic dysfunction. The overlap in dopaminergic pathway involvement makes dopamine agonists a logical therapeutic option when RLS features are present in a PD patient. RLS is believed to result from dysfunction in central dopaminergic pathways, especially those in the hypothalamic A11 nucleus, and sometimes from iron deficiency within the brain. In PD, the dopaminergic deficiency is central, and dopamine agonists (eg, pramipexole, ropinirole) act by stimulating dopamine receptors, potentially alleviating both parkinsonian symptoms and RLS-related discomfort. Recent research continues to support the role of dopaminergic modulation in managing RLS. A PD patient may present with motor symptoms like bradykinesia and rigidity, in addition to unpleasant sensations in the legs and an urge to move (typical of RLS). Dopamine agonists can help relieve these RLS symptoms, particularly when the patient\u2019s primary PD therapy may not fully cover these issues. Diagnosis is based on clinical history and examination. Differential diagnoses to consider include akathisia (a side effect from antipsychotics or other medications), nocturnal leg cramps, and neuropathic pain. A careful review of medication history and symptom pattern helps differentiate RLS from other similar movement disorders. First-line management of RLS involves the use of dopamine agonists (pramipexole, ropinirole, or rotigotine). If patients do not tolerate dopamine agonists or experience augmentation phenomena (worsening of symptoms), alternative agents like gabapentin may be considered. In the context of PD, where dopaminergic therapies are already used, careful titration is needed. Pregnancy and lactation considerations: Dopamine agonists are generally avoided in pregnancy unless the benefits justify the risk; non-pharmacologic strategies and close monitoring are advised. In lactating patients, the risk/benefit balance should be discussed with the patient. Option A (Dopamine agonist) is correct because dopamine agonists are first-line for idiopathic RLS and are effective in managing RLS features in PD. Option B (Gabapentin) is more often a second-line or alternative option, particularly in patients with painful RLS or those who cannot tolerate dopamine agonists. Options C and D either contain unclear material or merely state a description rather than a treatment modality. 1) Dopamine agonists are the mainstay for treating RLS, even in the setting of PD. 2) Always monitor for augmentation (worsening of symptoms) when using dopaminergic therapies for RLS. 3) A detailed medication and symptom history is vital to differentiate RLS from similar movement disorders like akathisia. The latest clinical guidelines and research continue to endorse the use of dopamine agonists as the first-line treatment for RLS. Recent studies emphasize the benefits of early identification and appropriate management of RLS in PD patients to improve quality of life while alerting clinicians to potential issues such as augmentation with long-term treatment.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "Around 70 yo male patient with recurrent fall, gait imbalance in the last 6 months On exam: masked face, vertical gaze palsy, retrocollus, bradykinesia. MRI showed\nWhat is the diagnosis:",
    "option_a": "PSP",
    "option_b": "MSA",
    "option_c": "LBD",
    "option_d": "CBD",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive Supranuclear Palsy (PSP) is an atypical parkinsonian syndrome and tauopathy. It presents with distinctive motor and oculomotor abnormalities that differentiate it from idiopathic Parkinson\u2019s disease. PSP is characterized by the accumulation of tau protein in neurons and glia, particularly in the brainstem, basal ganglia, and subthalamic regions. This leads to neuronal degeneration and the classic clinical findings such as vertical gaze palsy and postural instability. Retrocollis and falls are common due to midbrain involvement. Patients with PSP often exhibit a combination of parkinsonian features (bradykinesia, masked facies) along with specific signs such as vertical gaze palsy and retrocollis (neck extension). The clinical picture of recurrent falls and gait instability over months is highly suggestive of PSP. The differential diagnosis includes Multiple System Atrophy (MSA), Lewy Body Dementia (LBD), and Corticobasal Degeneration (CBD). In contrast to PSP, MSA often presents with autonomic dysfunction, LBD with early cognitive and visual hallucinations, and CBD with marked asymmetry and apraxia. Brain MRI in PSP typically shows midbrain atrophy (the 'hummingbird' sign). Management of PSP is primarily symptomatic. Levodopa is often trialed but usually offers minimal benefit. The treatment strategy includes physical and occupational therapy to reduce fall risk and improve mobility, along with supportive care. Research into tau-targeted therapies is ongoing. Although PSP predominantly affects the elderly, pregnancy and lactation are not applicable considerations in this patient population; however, when managing atypical parkinsonian syndromes in women of childbearing age, the risk profiles of medications must be carefully evaluated. Option A (PSP) is correct based on the classic presentation (vertical gaze palsy, recurrent falls, retrocollis, and parkinsonian features). Option B (MSA) is less likely due to the absence of significant autonomic dysfunction. Option C (LBD) typically features early cognitive decline and visual hallucinations, while Option D (CBD) usually exhibits asymmetry and cortical sensory deficits rather than the vertical gaze abnormalities seen in PSP. 1) Vertical gaze palsy, especially affecting downward gaze, is a hallmark of PSP. 2) Postural instability and frequent falls are early and prominent features. 3) MRI findings, like the hummingbird sign, support the diagnosis of PSP. Recent guidelines emphasize early recognition of PSP based on clinical and imaging findings. Although symptomatic therapy remains the mainstay, research into disease-modifying treatments targeting tau pathology is evolving.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  }
]